EP0638080A4 - PYRIMIDINE 7-BISUBSTITUEE-METHYL-4-OXO-3H -, 5H --PYRROLO 3,2-d -], UTILISATION PHARMACEUTIQUE ET COMPOSITIONS CONTENANT LADITE PYRIMIDINE. - Google Patents

PYRIMIDINE 7-BISUBSTITUEE-METHYL-4-OXO-3H -, 5H --PYRROLO 3,2-d -], UTILISATION PHARMACEUTIQUE ET COMPOSITIONS CONTENANT LADITE PYRIMIDINE.

Info

Publication number
EP0638080A4
EP0638080A4 EP93912081A EP93912081A EP0638080A4 EP 0638080 A4 EP0638080 A4 EP 0638080A4 EP 93912081 A EP93912081 A EP 93912081A EP 93912081 A EP93912081 A EP 93912081A EP 0638080 A4 EP0638080 A4 EP 0638080A4
Authority
EP
European Patent Office
Prior art keywords
pyrrolo
disubstituted
pyrimidine
oxo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93912081A
Other languages
German (de)
English (en)
Other versions
EP0638080A1 (fr
Inventor
Shri Niwas
John A Secrist Iii
John A Montgomery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocryst Pharmaceuticals Inc
Original Assignee
Biocryst Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharmaceuticals Inc filed Critical Biocryst Pharmaceuticals Inc
Publication of EP0638080A1 publication Critical patent/EP0638080A1/fr
Publication of EP0638080A4 publication Critical patent/EP0638080A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/35—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/40—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP93912081A 1992-04-21 1993-03-25 PYRIMIDINE 7-BISUBSTITUEE-METHYL-4-OXO-3H -, 5H --PYRROLO 3,2-d -], UTILISATION PHARMACEUTIQUE ET COMPOSITIONS CONTENANT LADITE PYRIMIDINE. Withdrawn EP0638080A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87144192A 1992-04-21 1992-04-21
US871441 1992-04-21
PCT/US1993/002841 WO1993021187A1 (fr) 1992-04-21 1993-03-25 PYRIMIDINE 7-BISUBSTITUEE-METHYL-4-OXO-3H^_, 5H^_-PYRROLO[3,2-d^_], UTILISATION PHARMACEUTIQUE ET COMPOSITIONS CONTENANT LADITE PYRIMIDINE

Publications (2)

Publication Number Publication Date
EP0638080A1 EP0638080A1 (fr) 1995-02-15
EP0638080A4 true EP0638080A4 (fr) 1995-08-23

Family

ID=25357439

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93912081A Withdrawn EP0638080A4 (fr) 1992-04-21 1993-03-25 PYRIMIDINE 7-BISUBSTITUEE-METHYL-4-OXO-3H -, 5H --PYRROLO 3,2-d -], UTILISATION PHARMACEUTIQUE ET COMPOSITIONS CONTENANT LADITE PYRIMIDINE.

Country Status (10)

Country Link
EP (1) EP0638080A4 (fr)
JP (1) JPH07507062A (fr)
KR (1) KR950701335A (fr)
AU (1) AU4276693A (fr)
CA (1) CA2133346A1 (fr)
FI (1) FI944933A0 (fr)
HU (1) HUT71559A (fr)
NO (1) NO303637B1 (fr)
RU (1) RU94046387A (fr)
WO (1) WO1993021187A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9809178A (pt) * 1997-05-29 2000-08-01 Novartis Ag 2-amino-7-(1-substituìdo-2-hidroxietil)-3,5-dihidro-pir rolo[3,2-d]pirimidin-4-onas
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
US6174888B1 (en) 1998-05-28 2001-01-16 Novartis Ag 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydropyrrolo[3,2-D]pyrimidin-4-ones
GB0215392D0 (en) * 2002-07-03 2002-08-14 Glaxo Group Ltd Chemical compounds
MXPA06002001A (es) * 2003-08-26 2006-06-20 Teijin Pharma Ltd Derivados pirrolopirimidinona.
US7557113B2 (en) 2003-08-26 2009-07-07 Teijin Pharma Limited Substituted pyrrolo[3,2-d]pyrimidine derivatives
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US7763257B2 (en) 2004-12-09 2010-07-27 Christina Juneau Compositions comprising transforming growth factor (TGF)-β1 and TGF-β2 in admixture of proteins obtained from dairy products
CA2710039C (fr) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarnazones et composes associes, et methodes de traitement du cancer
WO2010006438A1 (fr) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Composés inhibiteurs et procédés de traitement du cancer
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2072123C (fr) * 1989-10-31 2001-06-12 John A. Secrist, Iii Inhibiteurs de la phosphorylase du nucleoside de la purine
US5189039A (en) * 1989-11-29 1993-02-23 Biocryst, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo[3,2d]pyrimidine and pharmaceutical uses and compositions containing the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9321187A1 *

Also Published As

Publication number Publication date
FI944933A (fi) 1994-10-20
WO1993021187A1 (fr) 1993-10-28
CA2133346A1 (fr) 1993-10-28
NO943988L (no) 1994-10-20
NO303637B1 (no) 1998-08-10
NO943988D0 (no) 1994-10-20
EP0638080A1 (fr) 1995-02-15
KR950701335A (ko) 1995-03-23
HUT71559A (en) 1995-12-28
HU9403021D0 (en) 1994-12-28
FI944933A0 (fi) 1994-10-20
AU4276693A (en) 1993-11-18
RU94046387A (ru) 1996-09-27
JPH07507062A (ja) 1995-08-03

Similar Documents

Publication Publication Date Title
IL111422A0 (en) 10, 11 beta-c2-bridged steroids and pharmaceutical compositions containing the same
HU0500549D0 (en) Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
ZA939656B (en) Microvicidal compositions.
PH31205A (en) Pharmaceutical composition.
EP0598412A3 (fr) Composition pour la protection de la peau.
HUP9800792A3 (en) Benzylpiperidines and piperazines, their use and pharmaceutical compositions containing the same
ZA932646B (en) Cosmetic composition.
ZA936704B (en) Cosmetic composition.
EP0670716A4 (fr) Substances pharmaceutiques au gout camoufle.
EP0671929A4 (fr) Compositions.
ZA932586B (en) Cosmetic composition.
IL111533A0 (en) Quinoxalinedione derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
GB2271059B (en) Pharmaceutical compositions comprising aconitane derivatives and tetrahydroprotoberberine derivatives.
IL110988A0 (en) 4-arylamino-benzopyran derivatives and pharmaceutical compositions containing the same
PH31211A (en) Cosmetic composition.
OA09810A (en) Pharmaceutical composition.
HK58595A (en) Shampoo composition.
EP0638080A4 (fr) PYRIMIDINE 7-BISUBSTITUEE-METHYL-4-OXO-3H -, 5H --PYRROLO 3,2-d -], UTILISATION PHARMACEUTIQUE ET COMPOSITIONS CONTENANT LADITE PYRIMIDINE.
IL110809A0 (en) 1,5-diphenyl-3-pyrazolylalkyl-n-hydroxydithiocarbamates and pharmaceutical compositions containing them
EP0664115A3 (fr) Composition de shampoing.
ZA92110B (en) Pharmaceutical compositions.
HUP9903526A3 (en) Pyrimidine derivatives and pharmaceutical compositions containing the same
NZ234369A (en) 6-(naphthalenylethyl)-4-hydroxy-pyran-2-one derivatives and the 3,5-dihydroxyheptanoates; pharmaceutical compositions
EP0684832A4 (fr) Microemulsions contenant des compositions pharmaceutiques.
ZA918381B (en) Pharmaceutical compositions.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941019

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: EALICK, STEVE E.

Inventor name: GUIDA, WAYNE C.

Inventor name: ERION, MARK DAVID

Inventor name: MONTGOMERY, JOHN A.

Inventor name: SECRIST, JOHN A., III

Inventor name: NIWAS, SHRI

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980325

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19981006

RTI1 Title (correction)

Free format text: 7-DISUBSTITUTED-METHYL-4-OXO-3H -,5H --PYRROLO 3,2-D - PYRIMIDINE AND PHARMACEUTICAL USES AND COMPOSITIONS CONTAINING THE SAME